MLYS · Mineralys Therapeutics, Inc.
$25.75
-1.20 (-4.45%)
At close · Aug 20
Market Cap
$2.38B
Shares
88.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.75
Open$26.53
Day$25.30–26.62
52W close$14.61–47.33
Avg vol 30d719K
Short int9.3M · 10.5% float · 15.1d
Short vol51%
Last earningsAug 11, 2026
DataFeb 2023–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−3%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
34%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−12%
trailing
YTD return
−29%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $30 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.53% of float · ▼ -2.5% MoM · 15.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
226 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+37%
Y/Y
Balance sheet
$172.9M
net cash
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
34%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $27 › 200d $30 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.53% of float · ▼ -2.5% MoM · 15.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
226 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $15
Now $26 · 34%
Range high $47
vs 200-day avg -15%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLYS
this stock
Mineralys Therapeutics, Inc.
|
$2.38B | -29.0% | — | — | 10.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLYS | -1.3% | -4.6% | -12.0% | +0.9% | -29.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.7% | -7.9% | -23.2% | -1.2% | -40.9% |
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
219 filings
215 filers
Visit website
Investor relations